Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-04965842 + dabigatran
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**PF-04965842 + dabigatran** is a combination of two oral small molecule drugs: abrocitinib (PF-04965842), a selective Janus kinase 1 (JAK1) inhibitor developed for the treatment of moderate-to-severe atopic dermatitis, and dabigatran etexilate, an oral direct thrombin inhibitor used for stroke prevention in atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and postoperative thromboprophylaxis after hip replacement. Abrocitinib selectively inhibits JAK1, modulating immune signaling and reducing inflammatory markers, while dabigatran prevents the conversion of fibrinogen to fibrin, thereby inhibiting thrombus formation.
- Brand names
- CibinqoPradaxa
- Other names
- abrocitinibdabigatran etexilate
02
Targets
TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)F2 (Thrombin)JAK1 (Janus kinase 1)JAK3 (Janus kinase 3)
Beyond the preview
Go deeper on PF-04965842 + dabigatran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-04965842 + dabigatran.